Furthermore, differential gene expression analysis of baseline pre-treatment tumor biopsies between patients with PD and non-PD identified a 15 gene signature associated with clinical outcome, named here as MTL-CEBPA, Checkpoint Gene Signature or CCGS (Figures 5A and 5B). Here, CEBPA is linked to neoplasm.